Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

OBJECTIVES: To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate. METHODS: In this phase IIb study, 301 patients were randomised 2:1:1:1:1 to receive once da...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Rheum Dis
Hlavní autoři: Keystone, Edward C, Taylor, Peter C, Drescher, Edit, Schlichting, Douglas E, Beattie, Scott D, Berclaz, Pierre-Yves, Lee, Chin H, Fidelus-Gort, Rosanne K, Luchi, Monica E, Rooney, Terence P, Macias, William L, Genovese, Mark C
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2015
Témata:
Clinical and Epidemiological Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4316868/
https://ncbi.nlm.nih.gov/pubmed/25431052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2014-206478
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky